Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET).

Date publication

novembre 2019

Journal

Angiogenesis

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LUPORSI Elisabeth , Dr LORGIS Véronique , Dr JOUANNAUD Christelle

Tous les auteurs :
Vasseur A, Cabel L, Tredan O, Chevrier M, Dubot C, Lorgis V, Jacot W, Goncalves A, Debled M, Levy C, Ferrero JM, Jouannaud C, Luporsi E, Mouret-Reynier MA, Dalenc F, Lemonnier J, Savignoni A, Tanguy ML, Bidard FC, Pierga JY

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31773439

Résumé

Proof of concept studies has reported that circulating endothelial cell (CEC) count may be associated with the outcome of HER2-negative metastatic breast cancer (mBC) patients treated by chemotherapy and the anti-VEGF antibody bevacizumab. We report the results obtained in an independent prospective validation cohort (COMET study, NCT01745757).

Mots clés

Bevacizumab, Breast cancer, Circulating endothelial cells

Référence

Angiogenesis. 2019 Nov 26;: